1Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran
2Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Kerman
3Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran
4Islamic Azad University,Ahar Branch,Ahar,Iran
Breast cancer is the fifth most common cause of death among women worldwide. Resistance to cisplatin is a main challenge in its treatment. Our present aim was to prepare nanoniosomated cisplatin and examine its efficacy in vitro using the BT-20 cell line. Niosome nanoparticles containing cisplatin were prepared by reverse-phase evaporation and characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), spectrophotometry and MTT assay. The size and zeta potential of the nanodrug were estimated as 489.3 ± 23.66 nm and 23.4 ± 2.1 mV, respectively. Drug encapsuies confirmed appropriate retention of particles. Nanoparticles also increased the cytotoxic effects of cisplatin by 1.5 times compared to the standard drug. Findings of our study suggest that niosome nanoparticles are good carriers for cisplatin delivery to breast cancer cells.